REMD-477 (Volagidemab) + GLP-1
Obesity / Type 2 Diabetes
Phase 2 (planned)Active
Key Facts
About REMD Biotherapeutics
REMD Biotherapeutics is a clinical-stage biotech leveraging expertise in GPCR-targeting antibodies and bispecific platforms to develop novel treatments. Its lead asset, Volagidemab, is an anti-glucagon receptor antibody with promising Phase 2 data in Type 1 and Type 2 diabetes and is being explored in obesity and oncology-related hyperglycemia. The company operates with a dual-US/China footprint and has established key strategic partnerships, notably with GenScript ProBio and Buchang Pharmaceutical, to advance its pipeline and platform technologies.
View full company profileTherapeutic Areas
Other Obesity / Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| GLP-1 MAP Program | Vaxess Technologies | Pre-clinical |